Trial · NCT07887217

THE EFFECT OF A TRANSTHEORETICAL MODEL-BASED CHATBOT SUPPORT INTERVENTION ON SMOKING BEHAVIOR IN UNIVERSITY STUDENTS

NCT07887217, Not applicable, Active not recruiting, Seher DÖNER

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. THE EFFECT OF A TRANSTHEORETICAL MODEL-BASED CHATBOT SUPPORT INTERVENTION ON SMOKING BEHAVIOR IN UNIVERSITY STUDENTS. Trials, record NCT07887217. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887217

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: THE EFFECT OF A TRANSTHEORETICAL MODEL-BASED CHATBOT SUPPORT INTERVENTION ON SMOKING BEHAVIOR IN UNIVERSITY STUDENTS
NCT number: NCT07887217
Status: Active not recruiting
Phases: Not applicable
Enrollment: 100 participants, actual
Lead sponsor: Seher DÖNER
Conditions: Smoking ( Cigarette), Smoking (Tobacco) Addiction, Smoking Behaviors, Smoking Cessation, Tobacco Smoking
Interventions: Dumansız (Transtheoretical Model-Based Chatbot Support Intervention)
First posted: 2026-10-21
Last updated: 2026-10-21

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Participants Reporting Smoking Cessation at Week 6	At baseline, immediately after the six-week intervention (Week 6)	Smoking cessation status will be assessed by participant self-report. The outcome is the proportion of participants who report having stopped smoking cigarettes at Week 6, compared between the intervention and control groups.
Primary	Change in Stage of Change for Smoking Cessation from Baseline to Week 6	Baseline and Week 6	Stage of change will be assessed using the Stage of Change Questionnaire based on the Transtheoretical Model. Participants will be classified into precontemplation, contemplation, preparation, action, or maintenance. Change in stage from baseline to Week 6 will be evaluated and compared between the intervention and control groups.
Primary	Proportion of Participants Reporting Smoking Cessation at 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	The proportion of participants who report having stopped smoking 3 months after completion of the 6-week intervention.
Primary	Change in Stage of Change for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 months after completion of the 6-week intervention	Change in participants' stage of change for smoking cessation, classified as precontemplation, contemplation, preparation, action, or maintenance, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Smoking Cessation Self-Efficacy from Baseline to Week 6	Baseline and Week 6	Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to the end of the 6-week intervention period.
Secondary	Change in Smoking Cessation Self-Efficacy from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' smoking cessation self-efficacy scores, measured using the Self-Efficacy Scale, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Decisional Balance for Smoking Cessation from Baseline to Week 6	Baseline and Week 6	Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to Week 6.
Secondary	Change in Decisional Balance for Smoking Cessation from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' decisional balance scores regarding smoking cessation, measured using the Decisional Balance Scale, from baseline to 3 months after completion of the 6-week intervention.
Secondary	Change in Cigarette Craving Scores from Baseline to Week 6	Baseline and Week 6	Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to Week 6.
Secondary	Change in Cigarette Craving Scores from Baseline to 3 Months After the 6-Week Intervention	Baseline and 3 Months After the 6-Week Intervention	Change in participants' cigarette craving scores, measured using the Cigarette Craving Scale, from baseline to 3 months after completion of the 6-week intervention.

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07887217

GET https://conductscience.org/api/trials/v1/NCT07887217/registered

API reference For AI assistants